Impax Draws FTC Scrutiny for Tower Deal | McDermott

McDermott Will & Schulte, a global law firm

COVERAGE

Impax Draws FTC Scrutiny for Tower Deal

December 30, 2014

Read time: 2 min

Raymond Jacobsen and Jon Dubrow were noted as counsel to Impax Laboratories in the FTC’s antitrust review of the company’s proposed acquisition of privately held drugmaker Tower Holdings Inc. The FTC has extended its review of the $700 million transaction.

Jon B. Dubrow

Socio

Washington, DC

Raymond A. Jacobsen , Jr.

Socio

Washington, DC

You may also like